Imaging Biometrics, LLC

Imaging Biometrics develops quantitative medical imaging analysis software focused on neuro-oncology and brain tumor characterization. The company specializes in advanced post-processing algorithms and plugins that enhance MRI interpretation, particularly for contrast-enhanced imaging and perfusion analysis. Core product offerings include FTB Maps (for tumor characterization), IB Nimble (clinical workflow integration), IB Neuro (neuroimaging analysis with Delta T1 and rCBV mapping), IB Diffusion, IB DCE (dynamic contrast-enhanced imaging), IB Delta Suite, IB Rad Tech, and IB StoneChecker. The software leverages proprietary quantitative technology including Delta T1 (standardized T1 subtraction) and relative cerebral blood volume (rCBV) mapping to improve accuracy in assessing residual enhancing tumors, differentiating sellar lesions, and guiding surgical and therapeutic management. Products are designed for PACS compatibility and clinical implementation in hospital radiology departments and neuro-oncology centers. The company serves academic medical centers, community hospitals, and research institutions internationally, with particular strength in European and North American markets. Imaging Biometrics emphasizes clinical validation through peer-reviewed publications and collaborations with academic neuroradiologists and neuro-oncologists. Software is available as Mac plugins with free trial and demonstration options. The company maintains direct clinical support and works with institutional research teams on imaging-guided surgical planning and radiation therapy applications.